The news follows the recent recommendation of the human medicines committee (CHMP) of the European Medicine Agency (EMA) to authorise COVID-19 bivalent vaccines from both Pfizer/BioNTech and Moderna.
On Tuesday, the FDA approved Pfizer Inc’s (NYSE:PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower respiratory tract ...
NEW YORK, October 22, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE ... approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for ...